Antibodies against hepatitis B core antigen (anti-HBc) are found in combination with the hepatitis B surface antigen (HBsAg) in individuals who were infected and persist as Hepatitis B virus (HBV) carriers. The concomitance of anti-HBc plus the antibody against hepatitis B surface antigen (anti-HBs) means that the infected person cleared the HBsAg and became naturally immunized against HBV (W Szmuness et al. 1976 Am J Epidemiol 104: 256-262, E Feret et al. 1987 Am J Epidemiol 125: 140-149, ASF Lok et al. 1988 Hepatology 8: 766-770, BC Zanalda et al. 1990 . Anti-HBc could also be found as the sole serum marker of HBV infection (anti-HBc alone). This last serologic pattern is seen in: (i) the "window" phase of a recent acquired-HBV infection, before the onset of anti-HBs reactivity (ii) in HBV carriers with undetectable HBsAg levels; (iii) in people recovered from previous HBV infection, but having subsequently lost detectable anti-HBs; (iv) false positive test results (JI Dienstag & DM Ryan 1982 Am J Epidemiol 115: 26-39, Feret loc. cit., Lok loc. cit., Zanalda loc. cit.) . Indeed, Parkinson et al. (1990 J Med Virol 30: 253-257) showed weak specificity of anti-HBc tested by enzyme immunoassay (EIA) in comparison with anti-HBc screened by radio immunoassay (RIA). However, these authors found high concordance between these two methods when the EIA positive result was expressed as 70% or more of the total antibody-linking inhibition. In spite of all this knowledge controversies about the interpretation of the anti-HBc alone still remain.
Aiming to identify HBV markers prevalence in the population of N. Sra. do Livramento, a small municipality in the State of Mato Grosso, Central Brazil, an epidemiologic study was conducted between October 1993 and June 1994 (unpublished data). Sera from 740 individuals, a representative sample of the population, were collected, frozen at -20°C and sent to National Reference Center for Viral Hepatitis, Instituto Oswaldo Cruz (IOC), Rio de Janeiro, Brazil. HBsAg and anti-HBs were detected by EIA, using reactives produced by BioManguinhos, Rio de Janeiro, Brazil (EIA/BM â ). Anti-HBc was detected by EIA, using kits from IOC (EIA/IOC). Anti-HBc kit is produced using recombinant protein, in solid phase and specific polyclonal IgG labelled to peroxidase as conjugate.
Among the 740 participants of the population survey, 169 (22.8%) had at least one of the three HBV markers. A surprisingly high number, 83 (49.2%) out of 169, of anti-HBc alone was found, very different from those seen in other countries (Szmuness loc. cit., Dienstag & Ryan loc. cit., Feret loc. cit., Lok loc. cit.) . As this could have been caused by false-positive anti-HBc reactions, we decided to re-test sera using EIA reactives produced by other manufacturer: anti-HBc (Corzyme â ), HBsAg (Auszyme â ) and anti-HBs (Ausab â ) (Abbott, North Chicago, USA). This confirmatory part of the study was performed in the blood bank of Federal University of Mato Grosso.
Tests for anti-HBc were repeated in sera that showed the following results in the first screening: (i) 83 positive sera for anti-HBc alone; (ii) 58 sera positive for both anti-HBc and anti-HBs; (iii) 59 sera randomly selected among 571 negative samples for all HBV markers. Considering EIA (Corzyme â ) as gold-standard, sensitivity and specificity of the EIA/IOC were calculated and the agreement of the results obtained with these two kits were evaluated by the Youden's index J (P Armitage 1971 Statistical Methods in Medical Research p. 434-435, Blacwell Sc. Publ., London).
Seventy one (85.5%) sera remained anti-HBc positive when re-tested by EIA-Corzyme â . Of the 58 positive sera for both anti-HBc and anti-HBs, 57 (98.3%) had the anti-HBc positivity confirmed. All 59 sera negative for all HBV markers remained negative for Corzyme â . Agreement between the two EIA kits was observed in 187 (93.5%) from 200 re-tested samples (Youlden's index J = 0.82; IC 95% = 0.73-0.91). The calculated sensitivity and specificity for EIA/IOC in anti-HBc detection were 100% (128/128) and 82% (59/72), respectively. The false positive rate of this method was 9% (13/ 141) (Table) . able explanation for the high prevalence of antiHBc alone found by us and previously reported in other Brazilian studies is the low sensitivity from the anti-HBs detection rather than a high proportion of false positive anti-HBc results, particularly if EIA/BM â product is used. Probably, most individuals with an anti-HBc alone result by EIA/IOC is really a previously HBV infected that cleared HBsAg, but with undetectable anti-HBs level by EIA/BM â kits. The poor sensitivity of this method may produce a high amount of false negative results and an erroneous high proportion of anti-HBc alone subjects. HBsAg purified from plasma of asymptomatic blood donors is used in solid phase of EIA for anti-HBs detection and for enzyme-conjugated preparation. The great volume of plasma with high level of HBsAg required for the purification procedure precludes the production of a higher sensitive anti-HBs kit. More encouraging results could be obtained using recombinant HBsAg proteins.
In the present report we found high sensitivity and good specificity for the EIA/IOC in detection of anti-HBc. Probably, the lower specificity here observed is not important if one consider the usefulness of this method to screen blood donors. The high concordance found in results of anti-HBc tested by the two EIA kits and the absence of change in its overall prevalence after re-testing sera warrant that EIA/IOC is a suitable method to detect HBV contact in epidemiological surveys. In fact, to this goal is quite reasonable and less expensive not to use anti-HBs since the anti-HBc is more sensitive and has a better detection of previous HBV contact, except when dealing with anti-HBV vaccine response. 
